Statement: Health Canada Consultation, Codeine Products
Ottawa, September 11, 2017
The following statement can be attributed to Innovative Medicines Canada’s president, Pamela Fralick:
“Innovative Medicines Canada is supportive of the actions the federal government is taking to address the opioid crisis, including the ongoing consultation regarding the non-prescription availability of low-dose codeine products. Guided by the association’s Code of Ethical Practices, the innovative pharmaceutical industry is one of the most regulated industries in Canada and fully supports mechanisms that ensure Canadians have timely access to safe, effective, and high quality medicines and vaccines.”
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
– 30 –
For further information: